In the pivotal Phase III trial of pazopanib, PFS was significantly prolonged by pazopanib treatment compared with placebo, regardless of MSKCC risk ... well tolerated in mRCC with poor prognostic ...

Total Borrowings: $293.9 million as of December 31, 2024. Monroe Capital Corp (NASDAQ:MRCC) achieved an annualized dividend yield of 11.4%, indicating strong returns for shareholders. The company ...

Anemia and low performance status predict worse survival and greater risk for treatment failure in low-intermediate risk vs low-risk patients with mRCC treated with first-line ICI-based therapy.

Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...